This is the mail archive of the
ecos-bugs@sources.redhat.com
mailing list for the eCos project.
Yg5Y54 This st0ck has everything going for it
- From: "john gannon" <fineen at bcwrestling dot com>
- To: "Johnnie Christopherso" <ecos-devel at sources dot redhat dot com>
- Date: Sun, 27 Feb 2005 03:35:48 +0600
- Subject: Yg5Y54 This st0ck has everything going for it
- Reply-to: "john gannon" <fineen at bcwrestling dot com>
Martin Nutraceuticals Commences Expansion in Global Nutraceutical
Marketplace.
Watch MTNU on Thursday!
Martin Nutraceuticals Inc. (MTNU)
Approximate Float: 2.5 Million
Currently trading at: 0.91
30 Day Projection: 2.00
Martin Nutraceuticals Commences Expansion in Global Nutraceutical
Marketplace.
Press Release Source: Martin Nutraceuticals Inc.
Wednesday February 23, 12:01 pm ET
RENO, Nev., Feb. 23, 2005 PRIMEZONE. Martin Nutraceuticals Inc. (MTNU)
is a company focused on developing natural and alternative medicine
products that provide better health for individuals through the use of
their wide range of products, which aid in joint therapy, digestive
therapy, WeightControl, blood circulation and alertness, and overall
improved
functioning of the b0dy.
The flagship product which is based on Joint Therapy is used to aid in
joint and general arthritic pain. Over 65 million Americans suffer from
arthritis and osteoporosis. For several years, Dr. A. W. Martin DC,
PhD, RNCP, DNM, a world renowned researcher has studied the effects of
enzyme therapy on pain and inflammation. Dr. Martin has developed a unique
blend of proprietary and patented ``systemic oral enzymes'' designed to
provide superior anti-inflammatory benefits. Studies have shown that
Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain and
inflammation in 80% of patients who are diagnosed with Osteoarthritis of
the knees in less than 6-weeks.
In another study conducted the patient Fibromyalgia -- a severe muscle
pain syndrome that affects more than 20 million North Americans -- 90%
of patients reported relief from swelling and pain within 4-weeks of
using Dr. Martin's Joint Therapy formula.
The nutraceuticals market has grown steadily at an incredible rate of
15-20% annually since 1998. Currently in North America, over 3.9 billion
is spent on over-the-counter and prescription medication for arthritis,
joint and muscle related pain alone. Since Dr. Martin's foray into the
nutraceuticals market, Dr. Martin's products have amassed sales over 35
million. It is with this track record and knowledge that Martin
Nutraceuticals has re-branded many of Dr. Martin's successful formulas and
is
poised to unveil them onto an international platform.
In the weeks and months to come, the company will be unveiling new
product lines, various sales targets, contracts, distribution agreements
and clinical data.
About MTNU:
MTNU is becoming quickly recognized in the nutraceutical marketplace
which will surpass 74.4 billion in the year 2007. With a growing demand
for nutraceutical products that provide not only health benefits, but
also prevent and provide treatment for disease, MTNU provides high
quality products that use proprietary and patented oral systemic enzymes
that help in the rapid absorption of the product, resulting in incredibly
swift, and effective results to symptoms including:
JointPain
Cardiovascular Irregularities
Digestive Irregularities
Anti-Oxidization
WeightL0ss
MTNU offers individuals a wide array of reliable and effective
nutraceuticals. Martin Nutraceuticals has created a family of complimentary
medicine and supplementation that has helped thousands of people suffering
from arthritis and general jointpain, poor circulation, tiredness,
obesity and digestive complications. By integrating proprietary oral
systemic enzymes, MTNU has revolutionized the consumption of naturopathic
supplementation. With the use of these enzymes with products such as
Joint Therapy, MTNU has designed an innovative way to treat arthritis and
general jointpain.
Millions of people in North America suffer from some degree of general
jointpain. According to the Arthritis Society, arthritis is North
America's most common ailment, with over 44 million North Americans
suffering. The Wall Street Journal, in the April 19th, 1999 issue states
that
Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) killed 20,000
Americans a year and put another 100,000 in the hospital suffering with
drug
side effects including: liver damage, kidney damage and intestinal
hemorrhaging. With many of these products being pulled and highly
regulated because of the potential of deadly side effects, sufferers of
jointpain are seeking a natural, healthy alternative to aid in their
suffering.
MTNU has developed a proprietary therapeutic product, Joint Therapy,
which is able to benefit all types of arthritis from: Rheumatoid
Arthritis, sports injuries, pelvic inflammation to cardiac inflammation.
MTNU's
unique marketing program consists of heavily aired infomercials, direct
mailorder marketing and large pharmaceutical and retail chains.
Will MTNU explode higher as more and more investors become aware of the
stock? If you think so, you may not want to wait until it is too late.
Remember, timing your trade is critical.
Good Luck and Happy Trading.
Information within this publication contains future looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Any statements that
express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions
or future
events or performance are not statements of historical fact and may be
future looking statements. Future looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Future looking statements in this action may be identified
through
the use of words such as projects, foresee, expects, will, anticipates,
estimates, believes, understands or that by statements indicating
certain actions may, could, or might occur. These future-looking statements
are based on information currently available and are subject to a
number of risks, uncertainties and other factors that could cause MTNU 's
actual results, performance, prospects or opportunities to differ
materially from those expressed in, or implied by, these future-looking
statements. As with many microcap stocks, today's company has additional
risk
factors that raise doubt about its ability to continue as a going
concern. MTNU is not a reporting company registered under the Securities
Act
of 1934 and hence there is limited public information available about
the company. These risks, uncertainties and other factors include,
without limitation, the Company's growth expectations and ongoing funding
requirements, and specifically, the Company's growth prospects with
scalable customers. Other risks include the Company's limited operating
history, the Company's history of operating losses, consumers' acceptance,
the Company's use of licensed technologies, risk of increased
competition, the potential need for additional financing, the conditions
and
terms of any financing that is consummated, the limited trading market for
the Company's securities, the possible volatility of the Company's
stock price, the concentration of ownership, and the potential fluctuation
in the Company's operating results. The publisher of this report does
not represent that the information contained in this message states all
material facts or does not omit a material fact necessary to make the
statements therein not misleading. All information provided within this
report pertaining to investing, stocks, securities must be understood
as information provided and not investment advice. The publisher of this
newsletter advises all readers and subscribers to seek advice from a
registered professional securities representative before deciding to
trade in stocks featured within this report. None of the material within
this report shall be construed as any kind of investment advice or
solicitation. Many of these companies are on the verge of bankruptcy. You
can
lose all your money by investing in this stock. The publisher of this
report is not a registered investment expert. Subscribers should not
view information herein as legal, tax, accounting or investment advice.
Any reference to past performance(s) of companies are specially selected
to be referenced based on the favorable performance of these companies.
You would need perfect timing to achieve the results in the examples
given. There can be no assurance of that happening. Remember, as always,
past performance is not indicative of future results and a thorough due
diligence effort, including a review of a company's filings at sec gov
or edgar-online com when available, should be completed prior to
investing. All factual information in this report was gathered from public
sources, including but not limited to Company Websites and Company Press
Releases. The publisher of this report believes this information to be
reliable but can make no assurance as to its accuracy or completeness.
Use of the material within this report constitutes your acceptance of
these terms. In compliance with the Securities Act of 1933, Section17
b, The publisher of this newsletter discloses the receipt of ten
thousand dollars from a third party, not an officer, director or affiliate
shareholder for the circulation of this report. Be aware of an inherent
conflict of interest resulting from such compensation due to the fact
that this is a paid advertisement and is not without bias.The party that
paid us has a position in the stock they will sell at anytime without
notice. This could have a negative impact on the price of the stock.
I want to say Hi to all my new friends out there, those people who doubted
me and
play.Under coach Andy Reid, the Eagles never have lost after a bye, and the
regulars basically
quarter.Mitchell caught a 2yard pass from McNabb midway in the opening
period, then did his
yhebfsfskyj.n6natnndwj.wijafsedhiqdh9hqpt.gwawenlhseqwfycgd